175 related articles for article (PubMed ID: 18614762)
1. Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells.
Dai Y; Chen S; Pei XY; Almenara JA; Kramer LB; Venditti CA; Dent P; Grant S
Blood; 2008 Sep; 112(6):2439-49. PubMed ID: 18614762
[TBL] [Abstract][Full Text] [Related]
2. Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.
Dai Y; Chen S; Shah R; Pei XY; Wang L; Almenara JA; Kramer LB; Dent P; Grant S
Blood; 2011 Feb; 117(6):1947-57. PubMed ID: 21148814
[TBL] [Abstract][Full Text] [Related]
3. Dissecting the roles of checkpoint kinase 1/CDC2 and mitogen-activated protein kinase kinase 1/2/extracellular signal-regulated kinase 1/2 in relation to 7-hydroxystaurosporine-induced apoptosis in human multiple myeloma cells.
Pei XY; Li W; Dai Y; Dent P; Grant S
Mol Pharmacol; 2006 Dec; 70(6):1965-73. PubMed ID: 16940414
[TBL] [Abstract][Full Text] [Related]
4. Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK.
Dai Y; Rahmani M; Pei XY; Khanna P; Han SI; Mitchell C; Dent P; Grant S
Blood; 2005 Feb; 105(4):1706-16. PubMed ID: 15494423
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism.
Dai Y; Landowski TH; Rosen ST; Dent P; Grant S
Blood; 2002 Nov; 100(9):3333-43. PubMed ID: 12384435
[TBL] [Abstract][Full Text] [Related]
6. MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism.
Pei XY; Dai Y; Tenorio S; Lu J; Harada H; Dent P; Grant S
Blood; 2007 Sep; 110(6):2092-101. PubMed ID: 17540843
[TBL] [Abstract][Full Text] [Related]
7. Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.
Pei XY; Dai Y; Youssefian LE; Chen S; Bodie WW; Takabatake Y; Felthousen J; Almenara JA; Kramer LB; Dent P; Grant S
Blood; 2011 Nov; 118(19):5189-200. PubMed ID: 21911831
[TBL] [Abstract][Full Text] [Related]
8. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
Ma CX; Cai S; Li S; Ryan CE; Guo Z; Schaiff WT; Lin L; Hoog J; Goiffon RJ; Prat A; Aft RL; Ellis MJ; Piwnica-Worms H
J Clin Invest; 2012 Apr; 122(4):1541-52. PubMed ID: 22446188
[TBL] [Abstract][Full Text] [Related]
9. Enhancing CHK1 inhibitor lethality in glioblastoma.
Tang Y; Dai Y; Grant S; Dent P
Cancer Biol Ther; 2012 Apr; 13(6):379-88. PubMed ID: 22313687
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells.
Dai Y; Yu C; Singh V; Tang L; Wang Z; McInistry R; Dent P; Grant S
Cancer Res; 2001 Jul; 61(13):5106-15. PubMed ID: 11431348
[TBL] [Abstract][Full Text] [Related]
11. Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells.
Dai Y; Pei XY; Rahmani M; Conrad DH; Dent P; Grant S
Blood; 2004 Apr; 103(7):2761-70. PubMed ID: 14645003
[TBL] [Abstract][Full Text] [Related]
12. The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells.
Pei XY; Dai Y; Rahmani M; Li W; Dent P; Grant S
Clin Cancer Res; 2005 Jun; 11(12):4589-600. PubMed ID: 15958645
[TBL] [Abstract][Full Text] [Related]
13. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo.
Kim K; Kong SY; Fulciniti M; Li X; Song W; Nahar S; Burger P; Rumizen MJ; Podar K; Chauhan D; Hideshima T; Munshi NC; Richardson P; Clark A; Ogden J; Goutopoulos A; Rastelli L; Anderson KC; Tai YT
Br J Haematol; 2010 May; 149(4):537-49. PubMed ID: 20331454
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways.
Hahn M; Li W; Yu C; Rahmani M; Dent P; Grant S
Mol Cancer Ther; 2005 Mar; 4(3):457-70. PubMed ID: 15767555
[TBL] [Abstract][Full Text] [Related]
15. Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways.
Lunghi P; Giuliani N; Mazzera L; Lombardi G; Ricca M; Corradi A; Cantoni AM; Salvatore L; Riccioni R; Costanzo A; Testa U; Levrero M; Rizzoli V; Bonati A
Blood; 2008 Sep; 112(6):2450-62. PubMed ID: 18583568
[TBL] [Abstract][Full Text] [Related]
16. Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to ST1571.
Yu C; Dai Y; Dent P; Grant S
Cancer Biol Ther; 2002; 1(6):674-82. PubMed ID: 12642693
[TBL] [Abstract][Full Text] [Related]
17. Chk1 Inhibition Potently Blocks STAT3 Tyrosine705 Phosphorylation, DNA-Binding Activity, and Activation of Downstream Targets in Human Multiple Myeloma Cells.
Zhou L; Pei X; Zhang Y; Ning Y; Li L; Hu X; Chalasani SL; Sharma K; Nkwocha J; Yu J; Bandyopadhyay D; Sebti SM; Grant S
Mol Cancer Res; 2022 Mar; 20(3):456-467. PubMed ID: 34782371
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways.
Jia W; Yu C; Rahmani M; Krystal G; Sausville EA; Dent P; Grant S
Blood; 2003 Sep; 102(5):1824-32. PubMed ID: 12738674
[TBL] [Abstract][Full Text] [Related]
19. Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo.
Hamed H; Hawkins W; Mitchell C; Gilfor D; Zhang G; Pei XY; Dai Y; Hagan MP; Roberts JD; Yacoub A; Grant S; Dent P
Mol Cancer Ther; 2008 Mar; 7(3):616-29. PubMed ID: 18347148
[TBL] [Abstract][Full Text] [Related]
20. LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.
Barnard D; Diaz HB; Burke T; Donoho G; Beckmann R; Jones B; Barda D; King C; Marshall M
Invest New Drugs; 2016 Feb; 34(1):49-60. PubMed ID: 26612134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
